Treating a speech disorder before the child can speak

Design

Randomised controlled trial of start timing, with typically developing and usual-care comparison groups

Population

44 infants with classic galactosemia, randomised to begin before 6 months or at 15 months, all completing at 24 months

Primary outcome

Standardised speech and language assessment scores after intervention

Effect

Both intervention groups outperformed usual care; the group starting at or before 6 months had a proportion of clinically concerning scores equal to typically developing peers. No effect of sex, genotype or milk consumption

Speech and language disorders are usually diagnosed at two to four years, by which point the question is remediation. Babble Boot Camp asks whether they can be prevented instead, by intervening on precursor skills — cooing, babbling, turn-taking — in infancy.

The trial recruited 44 infants with classic galactosemia, a metabolic condition carrying a high risk of severe speech and language disorder, and randomised them to start the programme before 6 months or at 15 months, both finishing at 24 months. A speech-language pathologist coached caregivers in weekly telehealth sessions, and the caregivers delivered the activities daily at home. Typically developing children and children with galactosemia receiving usual care served as comparison groups.

Both intervention groups outperformed usual care on standardised assessments at the end. The group starting at or before 6 months did best, with a proportion of clinically concerning scores equal to that of the typically developing comparison group. No effect of sex, genotype or milk consumption was seen.

Two features make this worth watching beyond galactosemia. The delivery model — telehealth coaching of parents rather than direct therapy — is cheap and scales to places with almost no speech-language therapists. And the authors report trials already running in infants with Down syndrome and in preterm infants, which is where the approach would touch large numbers of children.

• Forty-four infants with one rare condition; the effect size does not transfer
• The model is caregiver-delivered with telehealth coaching, not clinic therapy
• Earlier start was better — before 6 months rather than at 15 months
• Watch the ongoing trials in Down syndrome and preterm infants
• In the meantime, refer high-risk infants for early speech-language input rather than waiting for delay

Why it matters

It reframes speech-language disorder in high-risk infants as potentially preventable rather than something to be diagnosed and then treated.

Don't overread it

This is a small trial in one rare metabolic condition; extension to other high-risk infants is being tested, not established.

The statistics, in plain English

With 22 infants in each intervention group, the comparisons rest on very small numbers and the report describes direction rather than effect sizes. That the earlier-start group matched typically developing peers on the proportion of concerning scores is striking but comes from a handful of children, and matching a comparison group on a proportion is a weaker claim than equivalence testing. The condition studied is rare, so the absolute number of children this specific finding applies to is small.

Read the rest in the app

You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.

Get Daily Doctor — free

Scan to keep reading on your phone. No account needed to start.